Niagen Bioscience Acquires Patent Portfolio from Queen's University Belfast, Securing Exclusive NR Technology
Niagen Bioscience announced that it has acquired a portfolio of existing patents covering nicotinamide riboside and its salt forms from Queen's University Belfast. The acquired portfolio comprises the core body of patents underpinning the production, composition, and commercial use of NR, encompassing foundational composition-of-matter patents covering crystal morphologies, methods of making NR and other NAD+ precursors, and global patent rights spanning multiple jurisdictions. Prior to this transaction, Niagen Bioscience previously held exclusive rights to these patents through long-standing licensing and joint ownership arrangements with QUB. With this acquisition, Niagen Bioscience now becomes the sole owner of this IP portfolio.
Trade with 70% Backtested Accuracy
Analyst Views on NAGE
About NAGE
About the author
Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000, marking a strategic expansion into the performance wellness segment, which is expected to accelerate the Canadian launch of next-generation clean energy pouches.
- Executive Appointment: Concurrently, the company appointed Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units, aiming to leverage his extensive experience in retail and brand building to drive business growth.
- Market Potential: According to Grand View Research, the global energy drinks market is projected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, while the nicotine pouch category is expected to expand from $5.4 billion to over $25 billion at a 29.6% CAGR, indicating strong growth potential for Doseology's market positioning.
- Product Innovation: Doseology's U.S. subsidiary is developing pouch-based offerings that blend caffeine, nootropics, and adaptogens, designed to provide sugar-free, smoke-free alternatives for professionals and wellness consumers seeking functional stimulation, further solidifying its competitive edge in the health tech sector.
Niagen Bioscience Introduces Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. with Patented Niagen® (Nicotinamide Riboside)
Launch of Tru Niagen® Beauty: Niagen Bioscience has introduced Tru Niagen® Beauty, the first beauty supplement in the U.S. featuring Niagen (nicotinamide riboside), aimed at enhancing skin, hair, and nail health through cellular support.
Key Ingredients and Benefits: The supplement contains a blend of clinically studied ingredients, including Astaxanthin, Hyaluronic Acid, Grape Seed Extract, Biotin, and Vitamin E, designed to improve skin hydration, elasticity, and overall beauty from within.
Market Growth Potential: The U.S. astaxanthin market is projected to grow significantly, reflecting increasing consumer demand for natural antioxidants and health supplements, while the global nutricosmetics market is also expected to expand rapidly.
Commitment to Scientific Research: Niagen Bioscience emphasizes its dedication to advancing healthspan through evidence-based innovations and rigorous scientific research, positioning itself as a leader in NAD+ science and healthy aging.
